Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms Involved

13 Aug 2019

Abstract excerpt

Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin-Goltz syndrome or Gorlin syndrome, is a rare multisystem disorder with an estimated prevalence of around 1 in 100,000 on average. Vismodegib, an oral smoothened (SMO) inhibitor that blocks the activation of the sonic hedgehog (SHH) pathway, is used in patients with NBCCS. We present an interesting case of a 38-year-old female with Gorlin-Goltz...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer and Skin Lesions
Share to Hedgehog Signaling Pathway Studies
Share to Neurofibromatosis and Schwannoma Cases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31616614
DOI: 10.7759/cureus.5383

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms InvolvedPMID 31616614Read ↗

Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome.Semantic proximity Read ↗

Targeting the hedgehog pathway to treat basal cell carcinoma.Semantic proximity Read ↗

Study protocol: Sonidegib for Nevoid Basal Cell Carcinoma (Gorlin) Syndrome and EADO stage IIb Sporadic BCC, a phase II Study (SIBLINGS TRIAL).EU CT n. 2024-515989-14-00Semantic proximity Read ↗

Sonic Hedgehog Signaling in Basal Cell Nevus SyndromeSemantic proximity Read ↗

Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.Semantic proximity Read ↗

Acquisition of drug resistance in basal cell nevus syndrome tumors through basal to squamous cell carcinoma transitionSemantic proximity Read ↗

Nevoid basal cell carcinoma syndrome (Gorlin syndrome)Semantic proximity Read ↗

Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling.Semantic proximity Read ↗

Variable expression of Gorlin syndrome may reflect complexity of the signalling pathway.Semantic proximity Read ↗

Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in gorlin syndromeSemantic proximity Read ↗

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and BeyondSemantic proximity Read ↗

Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.